First patients test novel Cancer-Fighting antibody in hope for tough tumors
NCT ID NCT06328673
Summary
This is the first study in people testing a new drug called DM919, which is designed to help the immune system fight cancer. Researchers want to find safe and effective doses when DM919 is given alone or combined with another cancer drug (pembrolizumab) to 160 adults with advanced solid tumors that have stopped responding to standard treatments. The study will monitor patients closely for side effects and early signs that the treatment is working against their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NEXT Oncology
San Antonio, Texas, 78216, United States
-
The Cancer Institute and Hospital, Chinese Academy of Medical Sciences(CAMS)
Beijing, China
Conditions
Explore the condition pages connected to this study.